Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Sep 3;21(1):762.
doi: 10.1186/s13063-020-04698-0.

Hydrocortisone to treat early bronchopulmonary dysplasia in very preterm infants: study protocol for a randomized controlled trial

Yuan He  1 , Yong Zhang  2 , Shuqiang Gao  3 , Xiaoling Wang  1 , Na He  1 , Deshuang Zhang  1 , Wenbin Dong  1   4   5 , Christian Wieg  6   7   8 , Xiaoping Lei  9   10   11
Affiliations

Hydrocortisone to treat early bronchopulmonary dysplasia in very preterm infants: study protocol for a randomized controlled trial

Yuan He et al. Trials. .

Abstract

Background: Bronchopulmonary dysplasia (BPD) is still a common complication in very premature infants. At present, there is no effective treatment for BPD. Glucocorticoids are drugs commonly used to prevent or treat BPD before and after birth. In very premature infants with high risk factors for BPD, early use of dexamethasone can reduce the rate of death and/or BPD but may cause long-term adverse neurodevelopmental outcomes. Hydrocortisone (HC), as an alternative drug to dexamethasone, has been increasingly used to prevent BPD. However, no study has reported the efficacy and safety of HC to treat early BPD diagnosed at postnatal day (PND) 28.

Methods: This study protocol is for a multicenter double-blind randomized controlled trial of low-dose HC in the treatment of early BPD. Early BPD infants will be randomly assigned to the HC treatment group or control group. Infants in the HC group will receive 0.5 mg/kg HC twice a day for 7 days and then 0.5 mg/kg HC once a day for 3 days. The control group will be given the same volume of placebo and no intervention on the basis of routine treatment. The primary outcome is survival without moderate or severe BPD at 36 weeks postmenstrual age. Secondary outcomes are the short- and long-term effects on growth, metabolism, neurodevelopment, and other possible complications.

Discussion: This trial will determine the efficacy and safety of low-dose HC administration compared to placebo for the reduction of moderate or severe BPD at 36 weeks postmenstrual age in very preterm infants with early BPD.

Trial registration: China Clinical Trial Registration Center ChiCTR1900021854 . Registered on 13 March 2019.

Keywords: Bronchopulmonary dysplasia; Hydrocortisone; Preterm infants.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

References

    1. Stoll BJ, Hansen NI, Bell EF, Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network et al. Trends in care practices, morbidity, and mortality of extremely preterm neonates, 1993-2012. JAMA. 2015;314:1039–1051. doi: 10.1001/jama.2015.10244. - DOI - PMC - PubMed
    1. Cheong Jeanie LY, Doyle LW. An update on pulmonary and neurodevelopmental outcomes of bronchopulmonary dysplasia. Semin Perinatol. 2018;42:478–484. doi: 10.1053/j.semperi.2018.09.013. - DOI - PubMed
    1. Stoecklin B, Simpson SJ, Pillow JJ. Bronchopulmonary dysplasia: rationale for a pathophysiological rather than treatment based approach to diagnosis. Paediatr Respir Rev. 2018;32:91–97. - PubMed
    1. Jobe AH, Bancalari E. Bronchopulmonary dysplasia. Am J Respir Crit Care Med. 2001;163:1723–1729. doi: 10.1164/ajrccm.163.7.2011060. - DOI - PubMed
    1. Bancalari E, Jain D. Bronchopulmonary dysplasia: can we agree on a definition? Am J Perinatol. 2018;35(6):537–540. doi: 10.1055/s-0038-1637761. - DOI - PubMed

Publication types

LinkOut - more resources